ABT-414 - Revision history

Lazy at 08:21, 18 January 2025

2025-01-18T08:21:21Z

← Older revision		Revision as of 01:21, 18 January 2025
Line 13:		Line 13:
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.		\|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.
	}}		\|overview=ABT-414 is an antibody-drug conjugate currently in Phase 1 clinical trials, designed to target EGFR-overexpressing glioblastoma cells, but has not yet received FDA approval. While it shows a median progression-free survival of 6.1 months, it is associated with significant eye toxicities, particularly blurred vision, indicating a cautionary approach is necessary due to its potential high toxicity and the challenges noted in early trials.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:32:23Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:32, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=2		\|usefulness_rating=2
	\|notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on healthy tissue. The phase 1 study highlighted challenges such as variable doses, study drug discontinuations due to toxicities, and small sample size, advising caution in evaluating efficacy parameters.		\|notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on healthy tissue. The phase 1 study highlighted challenges such as variable doses, study drug discontinuations due to toxicities, and small sample size, advising caution in evaluating efficacy parameters.
	\|~~category~~=Antibody-Drug Conjugates and other protein-drug conjugates		\|treatment_category=Antibody-Drug Conjugates and other protein-drug conjugates
	\|links=		\|links=
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.		\|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.
	}}		}}

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:21Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 11:		Line 11:
	\|category=Antibody-Drug Conjugates and other protein-drug conjugates		\|category=Antibody-Drug Conjugates and other protein-drug conjugates
	\|links=		\|links=
			\|toxicity_level=4
			\|toxicity_explanation=The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=ABT-414 |FDA_approval=No |used_for=Targeting EGFR overexpressing glioblastoma cells |clinical_trial_phase=Phase 1 |common_side_effects=Eye toxicities, especially blurred vision |OS_with=Not reached at a median follow-up of 5.8 months |PFS_with=6.1 months for all patients, 5.9 months for EGFR amplified patients |usefulness_rating=2 |notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on..."

2024-03-24T12:52:23Z

Created page with "{{TreatmentInfo |drug_name=ABT-414 |FDA_approval=No |used_for=Targeting EGFR overexpressing glioblastoma cells |clinical_trial_phase=Phase 1 |common_side_effects=Eye toxicities, especially blurred vision |OS_with=Not reached at a median follow-up of 5.8 months |PFS_with=6.1 months for all patients, 5.9 months for EGFR amplified patients |usefulness_rating=2 |notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on..."

New page

{{TreatmentInfo
|drug_name=ABT-414
|FDA_approval=No
|used_for=Targeting EGFR overexpressing glioblastoma cells
|clinical_trial_phase=Phase 1
|common_side_effects=Eye toxicities, especially blurred vision
|OS_with=Not reached at a median follow-up of 5.8 months
|PFS_with=6.1 months for all patients, 5.9 months for EGFR amplified patients
|usefulness_rating=2
|notes=ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on healthy tissue. The phase 1 study highlighted challenges such as variable doses, study drug discontinuations due to toxicities, and small sample size, advising caution in evaluating efficacy parameters.
|category=Antibody-Drug Conjugates and other protein-drug conjugates
|links=
}}